<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Terbinafine (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Terbinafine (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Terbinafine (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9922" href="/d/html/9922.html" rel="external">see "Terbinafine (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12313" href="/d/html/12313.html" rel="external">see "Terbinafine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52865493"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Terbinafine;</li>
<li>APO-Terbinafine;</li>
<li>Auro-Terbinafine;</li>
<li>DOM-Terbinafine [DSC];</li>
<li>LamISIL;</li>
<li>PMS-Terbinafine;</li>
<li>RIVA-Terbinafine [DSC];</li>
<li>Terbinafine-250</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54323354"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F9567989"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2b44e72-c508-46fe-b538-5b3b685f7a46">Tinea capitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea capitis:</b> Limited data available: <b>Note:</b> For <i>Microsporum</i> spp. infections, griseofulvin is preferred over terbinafine. If terbinafine is used, higher-dose regimens are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14761128','lexi-content-ref-Pierini.1998','lexi-content-ref-AAP.1','lexi-content-ref-15115516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14761128','lexi-content-ref-Pierini.1998','lexi-content-ref-AAP.1','lexi-content-ref-15115516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Standard-dose regimen: </i>Children and Adolescents: <b>Note:</b> Dosing based on 4 to 6 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31343780','lexi-content-ref-Bradley.2021','lexi-content-ref-14761128','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31343780','lexi-content-ref-Bradley.2021','lexi-content-ref-14761128','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">10 to &lt;20 kg: Oral: 62.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to 40 kg: Oral: 125 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Oral: 250 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of </i>
<i>therapy: </i> General: 6 weeks; Species-specific: <i>Trichophyton tonsurans</i>: 4 to 6 weeks; <i>Microsporum canis: </i>6 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16220086','lexi-content-ref-31343780','lexi-content-ref-14761128','lexi-content-ref-21436968','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16220086','lexi-content-ref-31343780','lexi-content-ref-14761128','lexi-content-ref-21436968','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Higher-dose regimen</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16220086','lexi-content-ref-18378354','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16220086','lexi-content-ref-18378354','lexi-content-ref-AAP.1'])">Ref</a></span>): Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;25 kg: Oral: 125 mg once daily for 6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">25 to 35 kg: Oral: 187.5 mg once daily for 6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;35 kg: Oral: 250 mg once daily for 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9091470','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9091470','lexi-content-ref-AAP.1'])">Ref</a></span>): Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 20 kg: Oral: 62.5 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;20 to 40 kg: Oral: 125 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: Oral: 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51191991"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, clearance is decreased ~50% in adult patients with CrCl ≤50 mL/minute.</p></div>
<div class="block dohp drugH1Div" id="F51191992"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; use is contraindicated in adults with chronic or active hepatic disease.</p></div>
<div class="block doa drugH1Div" id="F9567990"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9922" href="/d/html/9922.html" rel="external">see "Terbinafine (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous dosing</i>: <b>Oral:</b> 250 mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulsed dosing</i>
<i>(alternative dosing method) (off label)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Optimal dosing regimen not established. Pulsed dosing is less effective than continuous dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 mg once daily for 4 weeks, off for 4 weeks, then resume with 250 mg once daily for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22632057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22632057'])">Ref</a></span>) <b>or</b> 500 mg/day in 1 or 2 divided doses for 1 week repeated every 4 weeks for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31487828','lexi-content-ref-18444971','lexi-content-ref-16198776','lexi-content-ref-26087080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31487828','lexi-content-ref-18444971','lexi-content-ref-16198776','lexi-content-ref-26087080'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a430226d-899b-467b-89ea-5952ca87f98b">Sporotrichosis, lymphocutaneous and cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis, lymphocutaneous and cutaneous (alternative agent for patients who do not respond to itraconazole) (off-label use):</b>
<b>Oral:</b> 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>). Treat for 2 to 4 additional weeks after all lesions have resolved; usual duration is 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14998402','lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14998402','lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dermatophyte folliculitis (tinea barbae, Majocchi granuloma) (off-label use):</i>
<b>Oral:</b> 250 mg once daily; duration is typically 2 to 6 weeks or until clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14739517','lexi-content-ref-26765401','lexi-content-ref-19761557','lexi-content-ref-22435879','lexi-content-ref-Jackson.2019','lexi-content-ref-29344845','lexi-content-ref-28083794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14739517','lexi-content-ref-26765401','lexi-content-ref-19761557','lexi-content-ref-22435879','lexi-content-ref-Jackson.2019','lexi-content-ref-29344845','lexi-content-ref-28083794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea capitis (off-label use):</i>
<b>Oral:</b> 250 mg once daily for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24336943','lexi-content-ref-18478357','lexi-content-ref-Treat.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24336943','lexi-content-ref-18478357','lexi-content-ref-Treat.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris (alternative agent) (off-label use)</i>: <b>Note:</b> Alternative treatment for patients with extensive skin involvement or in whom topical therapy failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 mg once daily for 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2194715','lexi-content-ref-7999601','lexi-content-ref-18478357','lexi-content-ref-8089640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2194715','lexi-content-ref-7999601','lexi-content-ref-18478357','lexi-content-ref-8089640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis/tinea manuum (alternative agent) (off-label use): </i>
<b>Note:</b> Alternative treatment for patients with extensive skin involvement or in whom topical therapy failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 mg once daily for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23076898','lexi-content-ref-18478357','lexi-content-ref-9542675','lexi-content-ref-1911319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23076898','lexi-content-ref-18478357','lexi-content-ref-9542675','lexi-content-ref-1911319'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991526"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to &lt;50 mL/minute: Administer 50% of the usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18360572','lexi-content-ref-35102533','lexi-content-ref-23889207','lexi-content-ref-Jensen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18360572','lexi-content-ref-35102533','lexi-content-ref-23889207','lexi-content-ref-Jensen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Use of alternative agent may be preferred (expert opinion); has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18360572','lexi-content-ref-35102533','lexi-content-ref-23889207','lexi-content-ref-Jensen.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18360572','lexi-content-ref-35102533','lexi-content-ref-23889207','lexi-content-ref-Jensen.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (highly protein bound, large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound, large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Oral:</b> Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral:</b> Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988908"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Contraindicated in chronic or active hepatic disease.</p></div>
<div class="block arsc drugH1Div" id="F55855904"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Terbinafine may cause hepatotoxicity (ranging from mild and asymptomatic <b>increased serum transaminases</b> to <b>hepatic failure</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10215503','lexi-content-ref-9382559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10215503','lexi-content-ref-9382559'])">Ref</a></span>). Terbinafine liver injury may present as <b>hepatocellular hepatitis</b> or <b>cholestatic hepatitis</b>, with some cases progressing to vanishing bile duct syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27927037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27927037'])">Ref</a></span>). Most cases of hepatotoxicity are self-limited; although, persistent and severe hepatocellular injury cases have been reported, requiring discontinuation of therapy or in rare cases liver transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17192859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17192859'])">Ref</a></span>). Resolution may be delayed (eg, 3 to 6 months) following discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15751740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15751740'])">Ref</a></span>). Acute hepatic failure due to terbinafine therapy is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25232453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25232453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; possible mechanisms include immunologic (part of a hypersensitivity reaction) or a metabolically mediated effect (formation of mono-GSH conjugate which binds to hepatobiliary proteins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11258966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11258966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically within the first 4 to 6 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762471'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-A* 33:03 allele (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28043905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28043905'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe cutaneous adverse reactions (SCARs), including <b>Stevens Johnson syndrome/toxic epidermal necrolysis </b>(SJS/TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7817681','lexi-content-ref-27086495','lexi-content-ref-8745918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7817681','lexi-content-ref-27086495','lexi-content-ref-8745918'])">Ref</a></span>),<b> drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9737044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9737044'])">Ref</a></span>) and <b>acute generalized exanthematous pustulosis</b> (AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29336314','lexi-content-ref-29786933','lexi-content-ref-30255495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29336314','lexi-content-ref-29786933','lexi-content-ref-30255495'])">Ref</a></span>) have been reported. Other delayed cutaneous reactions include <b>pityriasis rosea</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26729964','lexi-content-ref-9580815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26729964','lexi-content-ref-9580815'])">Ref</a></span>), <b>lichenoid eruptions</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898398','lexi-content-ref-26938740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898398','lexi-content-ref-26938740'])">Ref</a></span>), symmetrical drug-related intertriginous and flexural erythema (SDRIFE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28244137','lexi-content-ref-27153516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28244137','lexi-content-ref-27153516'])">Ref</a></span>) and subacute<b> cutaneous lupus erythematosus </b>(SCLE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18564209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18564209'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions including SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied; SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-9737044','lexi-content-ref-24528911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-9737044','lexi-content-ref-24528911'])">Ref</a></span>), although AGEP may have a more rapid onset within 2 days (Ross 2018); re-exposure usually results in symptoms within 1 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-27086495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-27086495'])">Ref</a></span>). SCLE generally occurs within 4 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18564209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18564209'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (SCLE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18564209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18564209'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Terbinafine, an allylamine antifungal, is structurally similar to naftifine; although, documented cross-reactivity has not been established. No cross-reactivity between terbinafine and naftifine was noted on patch tests (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9731972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9731972'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Taste &amp; smell disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysgeusia </b>(including <b>ageusia</b>; bitter/sour &gt; salty/sweet) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16319619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16319619'])">Ref</a></span>) and <b>altered sense of smell</b> (including <b>anosmia</b>) may occur and severe cases resulting in decreased food intake, weight loss, <b>anxiety,</b> or <b>depression</b> have been reported. Resolution may be delayed (eg, several weeks to &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not well known; possible mechanisms include receptor dysfunction through the inhibition of cytochrome P450-dependent enzyme or alteration of the cell structure or function of taste-related neurons through interference of the cholesterol biosynthesis pathway (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9892929','lexi-content-ref-16319619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9892929','lexi-content-ref-16319619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; mean onset of taste loss was 35 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors </i>(taste disturbance):</p>
<p style="text-indent:-2em;margin-left:6em;">• Age (&gt;55 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877021'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of taste loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877021'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body mass index (&lt;21 kg/m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877021'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombotic microangiopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombotic microangiopathy </b>(TMA), including <b>thrombotic thrombocytopenic purpura </b>and<b> hemolytic-uremic syndrome</b>, have been reported rarely (some fatal). Recurrent<b> anemia</b> and <b>thrombocytopenia </b>may occur within 2 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25255772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25255772'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunological (anti-ADAMTS-13 antibodies may be increased) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25255772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25255772'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; in one case report, occurred within ~2 weeks after therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25255772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25255772'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F247732"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3%), skin rash (6%), urticaria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6%), dysgeusia (3%; may be severe and result in weight loss)<span class="lexi-table-link-container"> (<a aria-label="Dysgeusia table link" class="lexi-table-link" data-table-id="lexi-content-dysgeusia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dysgeusia')">table 1</a>)</span><span class="table-link" style="display:none;">Dysgeusia</span>, dyspepsia (4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dysgeusia" frame="border" id="lexi-content-dysgeusia" rules="all">
<caption style="text-align:center;">
<b>Terbinafine (Systemic): Adverse Reaction: Dysgeusia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Terbinafine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Terbinafine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">465</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (3%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Terbinafine (Systemic): Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Terbinafine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Terbinafine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">465</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Zaouak 2019), alopecia (Cohen 2020, Richert 2001), bullous dermatitis (Gupta 1998a), cutaneous lupus erythematosus (Lorentz 2008), erythema multiforme (Carstens 1994, Todd 1995), exacerbation of psoriasis (Cohen 2020, Gupta 1998a), exfoliative dermatitis (Gupta 1998a), lichenoid eruption (Cohen 2020), pityriasis rosea (George 2015), psoriasiform eruption (Cohen 2020), skin photosensitivity (Kuo 2014), Stevens-Johnson syndrome (Cohen 2020), toxic epidermal necrolysis (Carstens 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia (Doty 2005), cholestasis (Kyriakidis 2017), pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Aguilar 2001, Ornstein 1998), anemia (Filanovsky 2015), hemolytic-uremic syndrome, pancytopenia (Kovacs 1994), severe neutropenia (Kovacs 1994, Shapiro 1999), thrombocytopenia (Filanovsky 2015), thrombotic microangiopathy (Filanovsky 2015), thrombotic thrombocytopenic purpura (Filanovsky 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Kyriakidis 2017), hepatic failure (Song 2005), hepatic impairment, hepatocellular hepatitis (Kyriakidis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, drug reaction with eosinophilia and systemic symptoms (Gupta 1998), serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell (Lareb Netherlands Pharmacovigilance Centre 2013), anosmia (Lareb Netherlands Pharmacovigilance Centre 2013), anxiety, depression, fatigue, hypoesthesia, malaise, paresthesia, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, exacerbation of systemic lupus erythematosus (Cohen 2020), increased creatine phosphokinase in blood specimen, myalgia, rhabdomyolysis (Zhou 2020), systemic lupus erythematosus (Cohen 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F247745"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to terbinafine or any component of the formulation; chronic or active hepatic disease</p></div>
<div class="block war drugH1Div" id="F247730"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg, naftifine, butenafine); cross-sensitivity to terbinafine may exist.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Although rare, changes in the ocular lens and retina have been reported; discontinuation of therapy may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disease (Lupus): Precipitation or exacerbation of cutaneous or systemic lupus erythematosus has been observed; discontinue if signs and/or symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is contraindicated in patients with active or chronic hepatic disease; clearance is reduced by ~50% in hepatic cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal dysfunction (CrCl ≤50 mL/minute); clearance is reduced by ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Due to potential toxicity, confirmation of diagnostic testing of nail or skin specimens prior to treatment of onychomycosis or dermatomycosis is recommended.</p></div>
<div class="block foc drugH1Div" id="F247741"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F9566193"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9574689"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Terbinafine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $12.67 - $13.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865494"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LamISIL: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block exp drugH1Div" id="F10806645"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>25 mg/mL Oral Suspension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 25 mg/mL oral suspension may be made using tablets. Crush twenty 250 mg tablets and reduce to a fine powder. Add small amount of a 1:1 mixture of Ora-Sweet and Ora-Plus and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label "shake well" and "refrigerate". Stable 42 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52614122"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block adm drugH1Div" id="F9572845"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals.</p></div>
<div class="block sts drugH1Div" id="F9567979"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store below 25°C (77°F). Protect from light.</p></div>
<div class="block meg drugH1Div" id="F49037895"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Lamisil: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F020539s033lbl.pdf%23page%3D11&amp;token=tl2TF%2FN7uQcg6LBFyuEEp3LVTXEnAmrv7R6VOlh%2FVDiUp%2BWyp9xF7U6muxwwO%2F0%2BR2ulrBch4O8SsrPzdK3NXtGQH%2FL7HCzCOjXY0cXhwnSq8gYOs%2Fb0KMyWlthycU%2BN&amp;TOPIC_ID=15936" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf#page=11</a></p></div>
<div class="block usep drugH1Div" id="F53569855"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of onychomycosis of the toenail or fingernail due to susceptible dermatophytes (FDA approved in adults); has also been used in the treatment of tinea capitis.</p></div>
<div class="block mst drugH1Div" id="F9566184"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Terbinafine may be confused with terbutaline </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LamISIL may be confused with LaMICtal, Lomotil</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9567975"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>
<div class="block dri drugH1Div" id="F247734"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amoxapine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amoxapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Atomoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Terbinafine (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Dextromethorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Imipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lofepramine. The active metabolite of lofepramine is desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoclopramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Protriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Terbinafine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Trimipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F247747"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Published information related to the use of systemic terbinafine in pregnancy is limited (Gupta 1997a; Sarkar 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Systemic therapy for the treatment of onychomycosis or tinea capitis is not recommended during pregnancy (Kaul 2017; Murase 2014).</p></div>
<div class="block mopp drugH1Div" id="F53569773"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">AST/ALT prior to initiation, repeat if used &gt;6 weeks; some experts have suggested that repeat testing at 6 weeks is unnecessary (Patel 2017); CBC (if used &gt;6 weeks in immunocompromised patients).</p></div>
<div class="block pha drugH1Div" id="F247728"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results in fungal cell death.</p></div>
<div class="block phk drugH1Div" id="F247744"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: &gt;70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributed to sebum and skin predominantly.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Plasma: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic predominantly via CYP1A2, 3A4, 2C8, 2C9, and 2C19 to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 40% (as a result of first-pass metabolism).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal half-life: 200 to 400 hours; very slow release of drug from skin and adipose tissues occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">Effective half-life:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 11 years: 14.7 ± 4.3 hours (range: 9.8 to 25.7 hours) (Humbert 1998; Nejjam 1995).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~36 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Children and Adults: Within 2 hours (Abdel-Rahman 2005; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%, primarily as inactive metabolites); feces (20%) (Debruyne 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to 8 years: 1.41 ± 2.5 L/hour/kg (Abdel-Rahman 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.47 ± 0.21 L/hour/kg (Abdel-Rahman 2005).</p></div>
<div class="block phksp drugH1Div" id="F51160031"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In CrCl ≤50 mL/minute, terbinafine clearance is decreased 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In hepatic cirrhosis, terbinafine clearance is decreased 50%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390206"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lamifen | Lamisil | Negafen | Onchofin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Likana | Tacna | Terbinafina richet | Terekol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amisan | Amykal | Lamisil | Myconafin | Terbiderm | Terbinafin actavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo terbinafine | Genrx Terbinafine | Lamisil | Noumed terbinafine | Pharmacor Terbinafine | Sebifin | Tamsil | Terbihexal | Terbinafine | Terbinafine Actavis | Terbinafine an | Terbinafine Ga | Terbinafine sandoz | Terbix | Tinasil | Zabel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Derfin | Elvina | Infud | Mycofin | Mycofree | Skinabin | Terbex | Terbicon | Terbifin | Xfin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doc Terbinafine | Lamisil | Terbinafin ab | Terbinafine apotex | Terbinafine Aurobindo | Terbinafine EG | Terbinafine sandoz | Terbinafine teva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Onycal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fungofin | Lamisil | Myconafine | Terbinafin | Ternafin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ceremil | Cloridrato de terbinafina | Funtyl | Lamisil | Tertop | Zior</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Onymax | Terbifil | Terbinafin actavis | Terbinafin Axapharm | Terbinafin Helvepharm | Terbinafin teva | Terbinafin zentiva | Terbinax | Tineafin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Onycal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dermoxyl | Dicil | Elater | Farbicil | Finex | Lamisil | Micoset | Mucivil | Terbinafina | Terfex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei jia | Ding ke | Lamisil | Lan mei shu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bellex | Enisol | Farbicil | Filut | Funide | Funzal | Hongoderm | Incomic | K Micot | Kew | Lamicol | Lamisil | Terbiderm | Terbinafina | Tersag</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Onychon | Terbinafin actavis | Terbisil | Terfimed</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amiada | Dermatin | Lamisil | Myconormin | Onymax | Terbiderm | Terbigalen | Terbina Q | Terbinafin | Terbinafin Acis | Terbinafin AL | Terbinafin Beta | Terbinafin CT | Terbinafin Dura | Terbinafin Heumann | Terbinafin hexal | Terbinafin Kwizda | Terbinafin pfizer | Terbinafin puren | Terbinafin q-pharm | Terbinafin sandoz | Terbinafin Stada | Terbinafin teva | Terbinafin Winthrop | Terbinafin-1 A Pharma | Terbinafin-isis | Terbinafine Aurobindo</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafin 1a farma | Terbinafin hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Farbicil | Fungoter | Lamisil | Micostop | Mycelvan | Nafin | Terekol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dermoxil | Dicil | Exifine | Finex | Fungistat | Funide | Lamidizol | Lamisil | Micostop | Micozone | Terbifung | Terbilazar | Terbinafina | Terbinox | Terfin | Terfinamed</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafin | Terbinafin actavis | Terbinafin sandoz | Terbinafine Olainfarm | Terbinafine sandoz | Terbinafine terbano | Terbisil | Terbisil kid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fungisafe | Lamifen | Lamisil | Mycomic | Terbifungin | Terbin | Terbinasil | Trerbi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fungicare | Lamisil | Talixane | Terbinafina Alter | Terbinafina Aurobindo | Terbinafina aurovitas | Terbinafina Combix | Terbinafina Kern Pharma | Terbinafina Normon | Terbinafina Pensa | Terbinafina pharmacia | Terbinafina Teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafiini Enna | Terbinafin alternova | Terbinafin Bmm Pharma | Terbinafin Galderma | Terbinafin hexal | Terbinafin pfizer | Terbinafin Ratiopharm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fungster | Terbinafine Actavis | Terbinafine almus | Terbinafine Alter | Terbinafine Arrow | Terbinafine bailleul | Terbinafine biogaran | Terbinafine Cristers | Terbinafine EG | Terbinafine evolugen | Terbinafine Isomed | Terbinafine pfizer | Terbinafine qualimed | Terbinafine ranbaxy | Terbinafine ratiopharm | Terbinafine RPG | Terbinafine sandoz | Terbinafine zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafine | Terbinafine relonchem</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Chemiderm | Funger | Lamisil | Terbafin | Terbinafine Aurobindo | Terbinafine/Target | Terfinor | Terilam | Termisil | Ternafinol | Thateron | Zakofin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo terbinafine | Erbinol | Jmp terbinafine | Lamisil | Synbinafine | Tebinisil | Terbifin | Terbinafina Farmoz | Terbinafine teva | Terfung</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafin JGL | Terbinax | Verbinaf</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lamigard | Lamisil | Terbigen | Terbinafin Ratiopharm | Terbinafine pfizer | Terbinafine q pharma | Terbiner | Terbisil | Tineal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Interbi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fungafine | Fungasil | Lamater | Lamisil | Lanafine | Nailderm | Terbasil | Terbinafine rowa | Ternaf</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acbro | Af-ter | Bdterbin | Daskil | Elifin | Exifine | Finecure | Finlin | Fintrix | Fungixit t | Fungotek | Funter | Hifen | Ifin | Keptafine | Lamisil | Lamiterb | Micoside | Phyte | Sebifin | Skitofine | Tebif | Tebina | Tebisure | Teraderm | Terbest | Terbicip | Terbifix | Terbiforce | Terbikem | Terbimax | Terbin | Terbinaforce | Terbinator | Terbinax | Terbinext | Terbitotal | Terbivolt | Terbized | Terbocet | Terbofin | Terbol | Terbotac | Terfast | Terfaze | Terfung | Tergosil | Tersig | Texifen | Tinafine | Tinafix | Topcos | Trfy | Turfine | Tyza | Zimig | Zoterb | Zygter</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Daskil | Lamisil | Micutan | Onymax | Terbinafina | Terbinafina Arrow | Terbinafina Aurobindo | Terbinafina Doc | Terbinafina EG | Terbinafina Mgi | Terbinafina San | Terbinafina sandoz | Terbinafina tecnigen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terfinil | Tinasil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Lipnol | Nedoril | Ramitect | Tebinaceil | Terbinafine | Terbinafine hydrochloride f | Terbinafine pfizer | Terbinal | Terby | Terfinabine | Termisil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Finamark | Fungisil | Fungiter | Lamifen | Lamisil | Mycofin | Oncosil | Skinabin | Tebif | Terbex | Terbifin | Terbin | Terbinaforce | Terbinol | Terbisil | Terbitack</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bacxil | Binasil | Cellnafine | Celtenafin | Cinafine | Curasil | Demisil | Dongsung terbinafine | Ernafin | Inno.n terbinafine hcl | Jw terbinafine | Lamipin | Lamisil | Lamitin | Lamonan | Laniten | Lapiderm | Lespo | Limecin | Lonasil | M ternafine | Micosil | Mujonal | Namuzole | Natocil | Ramihu | Raminafine | Ronacil | Samsung terbinafine | Selbina | Selnapin | Sentoes | Seoul terbinafine hci | Tabianfine | Tabinafine | Tbf | Tebafine | Tebina | Tebisil | Telbina | Temisil | Tenabin | Tenavine | Terbi | Terbiclin | Terbifine | Terbigen | Terbil | Terbin | Terbina | Terbinafine | Terbinafine HCL | Terbinafine ss | Terbinarin | Terbinex | Terbini | Termina | Terna | Ternabi | Ternabin | Terpin m | Terzol | Uninapin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Exifine | Lamifen | Lamisil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo terbinafine | Boderm | Lamifen | Laminox | Lamisil | Terafan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Exifine | Lamisil | Terbinafin actavis | Terbinafin bijon | Terbinafin sandoz | Terbinafine Actavis | Terbinafine Bmm | Terbinafine sandoz | Terbisil | Terbisil kid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Doc Terbinafine | Lamisil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafine Olainfarm | Terbisil | Terbisil kid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lifongid | Onifine | Teguma | Terbinafine Gt | Terfine | Terix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abinifin | Allifort | Bifynason's | Binafex | Erbitrax | Erbitrax t | Fyterdin | Hudiclor | Lamisil | Losil t | Losil T | Mycelvan | Terbinafina | Terlisgen | Unasal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo terbinafine | Exifine | Lamisil | Lisim | Onchofin | Terbicip | Terbinafine Cadila | Ternafin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Multichris terbinafine | Terbinaforce</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafine | Terbinafine A | Terbinafine alpharma | Terbinafine apotex | Terbinafine Aurobindo | Terbinafine cf | Terbinafine Merck | Terbinafine PA | Terbinafine PCH | Terbinafine ratiopharm | Terbinafine sandoz | Terbinafine xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafin | Terbinafin Bmm Pharma | Terbinafin Copyfarm | Terbinafin hexal | Terbinafin orifarm | Terbinafine Aurobindo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo terbinafine | Deolate | Lamisil | Noumed terbinafine | Terbafin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dermoxyl | Finex | Fungustil | Funide | Lamidizol | Lamisil | Micofinal | Micostop | Micoterat | Micoterbin | Terbicel | Terbilab | Terbinafina | Terbisil | Terbispor | Terekol | Xilatril</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lamisil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ademac | Bina | Binafin | Binasil | Binzet | Caweda | Ckosil | Cutis | Daskil | Dermafin | Exinofin | Funasole | Funge | Fungi rid | Fungirid | Geosil | Lamicart | Lamisil | Lerbin | Logirid | Monofin | Mycoderm | Neoterbin | Novaterafine | Qtec | Retipro | Terabin | Terafin | Terbexin | Terbi | Terbicid | Terbiderm | Terbiderm forte | Terbifold | Terbilet | Terbimax | Terbimed | Terbin | Terbipearl | Terbisan | Terbiser | Terbisil | Terbitec | Terbix | Terbiz | Terbizor | Terbizor ds | Tersil | Tinabin | Tinadew | Tinea | Turbo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Afugin | Erfin | Lamisil | Myconafine | Onymax | Terbinafin Bmm Pharma | Terbinafina | Terbinafine 1A Pharma | Terbinafine Aurobindo | Terbisil | Terbisil kid | Zelefion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbinafine | Terbinafine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Daskyl | Fungster | Lamisil | Terbin | Terbinafina | Terbinafina almus | Terbinafina parke davis | Terbinafina Stada | Termycol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Finex | Lamisil | Limpex | Mircol | Terbiderm | Terbimax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Corbinal | Lamifen | Lamisil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Terbisil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atifin | Binafin | Bramisil | Cidocan | Exifine | Exiter | Fungoterbine | Lamisil | Medofloran | Onychon | Tebikur | Terbifin | Terbinafine | Terbinafine akrikhin | Terbinafine canon | Terbinafine hexal | Terbinafine mff | Terbinafine pfizer | Terbinafine sandoz | Terbinafine sar | Terbinafine teva | Terbinafine vertex | Terbinox | Terbisil | Termicon | Tigal sanovel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lamifen | Lamisil | Negafen | Pms-terbinafin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Azurifin | Lamisil | Terbinafin 2care4 | Terbinafin actavis | Terbinafin Agp | Terbinafin Arrow | Terbinafin Bmm Pharma | Terbinafin Copyfarm | Terbinafin ebb | Terbinafin Galderma | Terbinafin hexal | Terbinafin Ivax | Terbinafin Mylan | Terbinafin Nordic drugs | Terbinafin Ratiopharm | Terbinafin Stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Exifine | Lamisil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atifan | Lamisil | Terbinafine Arrow</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Brinaf | Lamisil | Mycodekan | Onychomed | Onychon | Terbinafin | Terbinafin actavis | Terbisil | Terfimed</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lamisil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Onycal | Terbinafine Winthrop | Terbisil | Tercyd | Tinasil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Corbinal | Laminox | Lamisil | Mikonafin | Mycocur | Tekfin | Terafin | Terbin | Terbisil | Terbonile | Terinateva | Terminus | Tigal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Camisan | Fungitech | Lamisil | Lisim | Terfine | Terfung</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Binafin | Exifine | Fungotek | Lamicon | Lamiderm | Lamifen | Mycofin | Terbinafin kv | Terbinafine | Terbinorm | Terbinox</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fungisafe | Terafine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbimax | Terbinafina | Terfenam | Terfiren | Unex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Farbicil | Lamisil | Ofanthel | Perten | Terbinafina | Terfex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">ADCO terbinafine | Arrow terbinafine | Binacil | Dermax | Finderm | Lamisil | Lamispor | Terbi Clear | Terbicil</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Sebifin | Terbane | Terbinaforce | Terbofin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lamisil | Terbifin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16220086">
<a name="16220086"></a>Abdel-Rahman SM, Herron J, Fallon-Friedlander S, Hauffe S, Horowitz A, Rivière GJ. Pharmacokinetics of terbinafine in young children treated for tinea capitis [published correction appears in <i>Pediatr Infect Dis J</i>. 2006;25(8):760]. <i>Pediatr Infect Dis J</i>. 2005;24(10):886-891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/16220086/pubmed" id="16220086" target="_blank">16220086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9101008">
<a name="9101008"></a>Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. <i>Ann Pharmacother</i>. 1997;31(4):445-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9101008/pubmed" id="9101008" target="_blank">9101008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10215503">
<a name="10215503"></a>Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. <i>N Engl J Med</i>. 1999;340(16):1292-1293. doi:10.1056/NEJM199904223401617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10215503/pubmed" id="10215503" target="_blank">10215503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11568763">
<a name="11568763"></a>Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. <i>J Am Acad Dermatol</i>. 2001;45(4):632-634. doi:10.1067/mjd.2001.117520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11568763/pubmed" id="11568763" target="_blank">11568763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9646122">
<a name="9646122"></a>Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole.<i> Int J Dermatol</i>. 1998;37(6):410-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9646122/pubmed" id="9646122" target="_blank">9646122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10173095">
<a name="10173095"></a>Angello JT, Voytovich RM, Jan SA. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine. <i>Am J Manag Care</i>. 1997;3(3):443-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10173095/pubmed" id="10173095" target="_blank">10173095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31343780">
<a name="31343780"></a>Bar J, Samuelov L, Sprecher E, Mashiah J. Griseofulvin vs terbinafine for paediatric tinea capitis: When and for how long. <i>Mycoses</i>. 2019;62(10):949-953. doi:10.1111/myc.12970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/31343780/pubmed" id="31343780" target="_blank">31343780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23076898">
<a name="23076898"></a>Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. <i>Cochrane Database Syst Rev</i>. 2012;10:CD003584. doi:10.1002/14651858.CD003584.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/23076898/pubmed" id="23076898" target="_blank">23076898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28244137">
<a name="28244137"></a>Bhari N, Sahni K, Dev T, Sharma VK. Symmetrical drug-related intertriginous and flexural erythema (Baboon syndrome) induced by simultaneous exposure to oral and topical terbinafine. <i>Int J Dermatol</i>. 2017;56(8):e168-e170. doi:10.1111/ijd.13581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/28244137/pubmed" id="28244137" target="_blank">28244137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9892929">
<a name="9892929"></a>Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. <i>Br J Dermatol</i>. 1998;139(4):747-748. doi:10.1046/j.1365-2133.1998.02485.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9892929/pubmed" id="9892929" target="_blank">9892929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14739517">
<a name="14739517"></a>Bonifaz A, Ramírez-Tamayo T, Saúl A. Tinea barbae (tinea sycosis): experience with nine cases. <i>J Dermatol</i>. 2003;30(12):898-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/14739517/pubmed" id="14739517" target="_blank">14739517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2021">
<a name="Bradley.2021"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7817681">
<a name="7817681"></a>Carstens J, Wendelboe P, Søgaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. <i>Acta Derm Venereol</i>. 1994;74(5):391-392. doi:10.2340/0001555574391392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7817681/pubmed" id="7817681" target="_blank">7817681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998402">
<a name="14998402"></a>Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. <i>Mycoses</i>. 2004;47(1-2):62-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/14998402/pubmed" id="14998402" target="_blank">14998402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26765401">
<a name="26765401"></a>Chou WY, Hsu CJ. A case report of Majocchi's granuloma associated with combined therapy of topical steroids and adalimumab. <i>Medicine (Baltimore)</i>. 2016;95(2):e2245. doi:10.1097/MD.0000000000002245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26765401/pubmed" id="26765401" target="_blank">26765401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898398">
<a name="32898398"></a>Cohen PR, Erickson CP, Calame A. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. <i>Dermatol Online J</i>. 2020;26(7):13030/qt9jh9p0xp.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/32898398/pubmed" id="32898398" target="_blank">32898398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11475469">
<a name="11475469"></a>Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. <i>Clin Pharmacokinet</i>. 2001;40(6):441-472. doi:10.2165/00003088-200140060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11475469/pubmed" id="11475469" target="_blank">11475469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2194715">
<a name="2194715"></a>del Palacio Hernandez A, López Gómez S, González Lastra F, Moreno Palancar P, Iglesias Díez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. <i>Clin Exp Dermatol.</i> 1990;15(3):210-216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/2194715/pubmed" id="2194715" target="_blank">2194715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16319619">
<a name="16319619"></a>Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. <i>Laryngoscope</i>. 2005;115(11):2035-2037. doi:10.1097/01.MLG.0000181462.08683.0C<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/16319619/pubmed" id="16319619" target="_blank">16319619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9217846">
<a name="9217846"></a>Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to terbinafine. <i>Br J Dermatol</i>. 1997;136(6):976-977. doi:10.1111/j.1365-2133.1997.tb03954.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9217846/pubmed" id="9217846" target="_blank">9217846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378354">
<a name="18378354"></a>Elewski BE, Cáceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. <i>J Am Acad Dermatol</i>. 2008;59(1):41-54. doi:10.1016/j.jaad.2008.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/18378354/pubmed" id="18378354" target="_blank">18378354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18360572">
<a name="18360572"></a>Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. <i>Ther Clin Risk Manag</i>. 2005;1(4):299-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/18360572/pubmed" id="18360572" target="_blank">18360572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24336943">
<a name="24336943"></a>El-Khalawany M, Shaaban D, Hassan H, et al. A multicenter clinicomycological study evaluating the spectrum of adult tinea capitis in Egypt. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2013;22(4):77-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24336943/pubmed" id="24336943" target="_blank">24336943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7999601">
<a name="7999601"></a>Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. <i>Br J Dermatol</i>. 1994;131(5):684-686. doi:10.1111/j.1365-2133.1994.tb04983.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7999601/pubmed" id="7999601" target="_blank">7999601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25255772">
<a name="25255772"></a>Filanovsky K, Sigler E, Shvidel L. Thrombotic thrombocytopenic purpura following terbinafine therapy. <i>J Clin Apher</i>. 2015;30(1):58-59. doi:10.1002/jca.21359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/25255772/pubmed" id="25255772" target="_blank">25255772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11927703">
<a name="11927703"></a>Friedlander SF, Aly R, Krafchik B, et al; Tinea Capitis Study Group. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. <i>Pediatrics</i>. 2002;109(4):602-607. doi:10.1542/peds.109.4.602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11927703/pubmed" id="11927703" target="_blank">11927703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19761557">
<a name="19761557"></a>Gega A, Ketsela G, Glavin FL, Soldevilla-Pico C, Schain D. Majocchi's granuloma after antithymocyte globulin therapy in a liver transplant patient. <i>Transpl Infect Dis</i>. 2010;12(2):143-145. doi:10.1111/j.1399-3062.2009.00454.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/19761557/pubmed" id="19761557" target="_blank">19761557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26729964">
<a name="26729964"></a>George A, Bhatia A, Kanish B, Williams A. Terbinafine induced pityriasis rosea-like eruption. <i>Indian J Pharmacol</i>. 2015;47(6):680-681. doi:10.4103/0253-7613.169574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26729964/pubmed" id="26729964" target="_blank">26729964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9731972">
<a name="9731972"></a>Goday JJ, González-Güemes M, Yanguas I, Ilardia R, Soloeta R. Allergic contact dermatitis from naftifine in a child without cross-reaction to terbinafine. <i>J Eur Acad Dermatol Venereol</i>. 1998;11(1):72-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9731972/pubmed" id="9731972" target="_blank">9731972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2019">
<a name="Goldstein.2019"></a>Goldstein AO, Bhatia N. Onychomycosis: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14761128">
<a name="14761128"></a>Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. <i>J Eur Acad Dermatol Venereol</i>. 2003;17(6):627-640. doi:10.1046/j.1468-3083.2003.00691.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/14761128/pubmed" id="14761128" target="_blank">14761128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia.</i> 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9580815">
<a name="9580815"></a>Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. <i>Br J Dermatol</i>. 1998a;138(3):529-532. doi:10.1046/j.1365-2133.1998.02140.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9580815/pubmed" id="9580815" target="_blank">9580815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22632057">
<a name="22632057"></a>Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. <i>J Eur Acad Dermatol Venereol</i>. 2013;27(3):267-272. doi:10.1111/j.1468-3083.2012.04584.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/22632057/pubmed" id="22632057" target="_blank">22632057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9737044">
<a name="9737044"></a>Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. <i>Australas J Dermatol</i>. 1998b;39(3):171-172. doi:10.1111/j.1440-0960.1998.tb01275.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9737044/pubmed" id="9737044" target="_blank">9737044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9418768">
<a name="9418768"></a>Gupta AK, Shear NH. Terbinafine: an update. <i>J Am Acad Dermatol</i>. 1997a;37(6):979-988. doi:10.1016/s0190-9622(97)70076-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9418768/pubmed" id="9418768" target="_blank">9418768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9091470">
<a name="9091470"></a>Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. <i>J Am Acad Dermatol</i>. 1997b;36(3, pt 1):395-402. doi:10.1016/s0190-9622(97)80215-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9091470/pubmed" id="9091470" target="_blank">9091470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35102533">
<a name="35102533"></a>Gupta AK, Venkataraman M, Talukder M. Onychomycosis in older adults: prevalence, diagnosis, and management. <i>Drugs Aging</i>. 2022;39(3):191-198. doi:10.1007/s40266-021-00917-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/35102533/pubmed" id="35102533" target="_blank">35102533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9382559">
<a name="9382559"></a>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. <i>Arch Dermatol</i>. 1997;133(10):1213-1219. doi:10.1001/archderm.133.10.1213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9382559/pubmed" id="9382559" target="_blank">9382559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24636655">
<a name="24636655"></a>Hawkins DM, Smidt AC. Superficial fungal infections in children. <i>Pediatr Clin North Am</i>. 2014;61(2):443-455. doi:10.1016/j.pcl.2013.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24636655/pubmed" id="24636655" target="_blank">24636655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9818707">
<a name="9818707"></a>Humbert H, Denouël J, Cabiac MD, Lakhdar H, Sioufi A. Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration. <i>Biopharm Drug Dispos</i>. 1998;19(7):417-423. doi:10.1002/(sici)1099-081x(199810)19:7&lt;417::aid-bdd111&gt;3.0.co;2-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9818707/pubmed" id="9818707" target="_blank">9818707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22435879">
<a name="22435879"></a>Ilkit M, Durdu M, Karakaş M. Majocchi's granuloma: a symptom complex caused by fungal pathogens. <i>Med Mycol</i>. 2012;50(5):449-457. doi:10.3109/13693786.2012.669503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/22435879/pubmed" id="22435879" target="_blank">22435879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23889207">
<a name="23889207"></a>Irimie M, Tătaru A, Oantă A, Moga M. In vitro susceptibility of dermatophytes isolated from patients with end-stage renal disease: a case-control study. <i>Mycoses</i>. 2014;57(3):129-134. doi:10.1111/myc.12114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/23889207/pubmed" id="23889207" target="_blank">23889207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11258966">
<a name="11258966"></a>Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. <i>Chem Res Toxicol</i>. 2001;14(2):175-181. doi:10.1021/tx0002029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11258966/pubmed" id="11258966" target="_blank">11258966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jackson.2019">
<a name="Jackson.2019"></a>Jackson JD. Infectious folliculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27153516">
<a name="27153516"></a>Janjua SA, Pastar Z, Iftikhar N, Ammad S. Intertriginous eruption induced by terbinafine: a review of baboon syndrome. <i>Int J Dermatol</i>. 2017;56(1):100-103. doi:10.1111/ijd.13292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/27153516/pubmed" id="27153516" target="_blank">27153516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jensen.1">
<a name="Jensen.1"></a>Jensen JC. Pharmacokinetics of Lamisil® in humans. <i>J Dermatol Treat</i>. 1990;1(suppl 2):15-18. doi:10.3109/09546639009089024</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7772471">
<a name="7772471"></a>Jones TC. Overview of the use of terbinafine (Lamisil) in children. <i>Br J Dermatol</i>. 1995;132(5):683-689. doi:10.1111/j.1365-2133.1995.tb00711.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7772471/pubmed" id="7772471" target="_blank">7772471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(10):1255-1265. doi:10.1086/522765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28979861">
<a name="28979861"></a>Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. <i>Indian Dermatol Online J</i>. 2017;8(5):310-318. doi:10.4103/idoj.IDOJ_169_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/28979861/pubmed" id="28979861" target="_blank">28979861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7929931">
<a name="7929931"></a>Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. <i>J Am Acad Dermatol</i>. 1994;31(5, pt 1):806. doi:10.1016/s0190-9622(09)80049-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7929931/pubmed" id="7929931" target="_blank">7929931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28762471">
<a name="28762471"></a>Kramer ON, Albrecht J. Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised yopic. <i>Br J Dermatol</i>. 2017;177(5):1279-1284. doi:10.1111/bjd.15854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/28762471/pubmed" id="28762471" target="_blank">28762471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24656267">
<a name="24656267"></a>Kuo S, Sivamani RK. UVB-sensitive solar urticaria possibly associated with terbinafine. <i>Dermatol Online J</i>. 2014;20(3):doj_21753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24656267/pubmed" id="24656267" target="_blank">24656267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927037">
<a name="27927037"></a>Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. <i>Expert Opin Drug Saf</i>. 2017;16(2):149-165. doi:10.1080/14740338.2017.1270264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/27927037/pubmed" id="27927037" target="_blank">27927037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lamisil.1">
<a name="Lamisil.1"></a>Lamisil granules (terbinafine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lamisil.2">
<a name="Lamisil.2"></a>Lamisil tablets (terbinafine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lamisil.3">
<a name="Lamisil.3"></a>Lamisil (terbinafine hydrochloride) [product monograph]. Dorval, Quebec, Canada: Novartis Consumer Canada Inc; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lareb.1">
<a name="Lareb.1"></a>Lareb Netherlands Pharmacovigilance Centre. Terbinafine and smell alterations. https://databankws.lareb.nl/Downloads/KWB_2013_1_terbi.pdf. Published May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18564209">
<a name="18564209"></a>Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. <i>J Dtsch Dermatol Ges</i>. 2008;6(10):823-828. doi:10.1111/j.1610-0387.2008.06806.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/18564209/pubmed" id="18564209" target="_blank">18564209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27086495">
<a name="27086495"></a>Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. <i>Am J Med</i>. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/27086495/pubmed" id="27086495" target="_blank">27086495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad DermatolN</i>. 2014;70(3):401. doi: 10.1016/j.jaad.2013.09.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed March 9, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7756158">
<a name="7756158"></a>Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. <i>Br J Dermatol</i>. 1995;132(1):98-105. doi:10.1111/j.1365-2133.1995.tb08632.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7756158/pubmed" id="7756158" target="_blank">7756158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21436968">
<a name="21436968"></a>Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. <i>Clin Cosmet Investig Dermatol</i>. 2009;2:49-63. doi:10.2147/ccid.s3690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/21436968/pubmed" id="21436968" target="_blank">21436968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28043905">
<a name="28043905"></a>Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. <i>Gastroenterology</i>. 2017;152(5):1078-1089. doi:10.1053/j.gastro.2016.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/28043905/pubmed" id="28043905" target="_blank">28043905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336314">
<a name="29336314"></a>Olivier S, De Montjoye L, Tromme I, Baeck M. Two cases of annular acute generalized exanthematous pustulosis induced by terbinafine. <i>Eur J Dermatol</i>. 2018;28(2):236-238. doi:10.1684/ejd.2017.3199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/29336314/pubmed" id="29336314" target="_blank">29336314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9843023">
<a name="9843023"></a>Ornstein DL, Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. <i>J Am Acad Dermatol</i>. 1998;39(6):1023-1024. doi:10.1016/s0190-9622(98)70284-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9843023/pubmed" id="9843023" target="_blank">9843023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29188282">
<a name="29188282"></a>Patel D, Castelo-Soccio LA, Rubin AI, Streicher JL. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis. <i>JAMA Dermatol</i>. 2017;153(12):1326-1327. doi:10.1001/jamadermatol.2017.4483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/29188282/pubmed" id="29188282" target="_blank">29188282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17192859">
<a name="17192859"></a>Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. <i>Liver Transpl</i>. 2007;13(1):162-164. doi:10.1002/lt.21034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/17192859/pubmed" id="17192859" target="_blank">17192859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pierini.1998">
<a name="Pierini.1998"></a>Pierini AM, Soliani A, Hernandez M, Garcia-Diaz kR, Gonzalez MT, Santos P. Treatment of tinea capitis due to Microsporum canis with oral terbinafine: 40 cases. <i>Pediatric Dermatology</i>. 1998. Poster abstract P145.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25232453">
<a name="25232453"></a>Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World J Hepatol</i>. 2014;6(8):601-612. doi:10.4254/wjh.v6.i8.601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/25232453/pubmed" id="25232453" target="_blank">25232453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11736917">
<a name="11736917"></a>Richert B, Uhoda I, De la Brassinne M. Hair loss after terbinafine treatment. <i>Br J Dermatol</i>. 2001;145(5):842. doi:10.1046/j.1365-2133.2001.04423.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11736917/pubmed" id="11736917" target="_blank">11736917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29786933">
<a name="29786933"></a>Ross CL, Shevchenko A, Mollanazar NK, Hsu S, Motaparthi K. Acute generalized exanthematous pustulosis due to terbinafine. <i>Dermatol Ther</i>. 2018;31(4):e12617. doi:10.1111/dth.12617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/29786933/pubmed" id="29786933" target="_blank">29786933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12931704">
<a name="12931704"></a>Sarkar M, Rowland K, Koren G. Pregnancy outcomes following gestational exposure to terbinafine: a prospective comparative study. Abstracts of the Teratology Society 43rd Annual Meeting. June 21-26, 2003. <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(5):313-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/12931704/pubmed" id="12931704" target="_blank">12931704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2229529">
<a name="2229529"></a>Savin RC. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. <i>J Am Acad Dermatol</i>. 1990;23(4, pt 2):807-809. doi:10.1016/0190-9622(90)70294-r<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/2229529/pubmed" id="2229529" target="_blank">2229529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10354111">
<a name="10354111"></a>Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. <i>Br J Dermatol</i>. 1999;140(6):1196-1197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10354111/pubmed" id="10354111" target="_blank">10354111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31487828">
<a name="31487828"></a>Sprenger AB, Purim KSM, Sprenger F, Queiroz-Telles F. A week of oral terbinafine pulse regimen every three months to treat all dermatophyte onychomycosis. <i>J Fungi (Basel)</i>. 2019;5(3):82. doi:10.3390/jof5030082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/31487828/pubmed" id="31487828" target="_blank">31487828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15751740">
<a name="15751740"></a>Song JC, Deresinski S. Hepatotoxicity of antifungal agents. <i>Curr Opin Investig Drugs</i>. 2005;6(2):170-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/15751740/pubmed" id="15751740" target="_blank">15751740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8877021">
<a name="8877021"></a>Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. <i>Br J Clin Pharmacol</i>. 1996;42(3):313-318. doi:10.1046/j.1365-2125.1996.04105.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/8877021/pubmed" id="8877021" target="_blank">8877021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18444971">
<a name="18444971"></a>Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). <i>Mycoses</i>. 2009;52(1):72-76. doi:10.1111/j.1439-0507.2008.01531.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/18444971/pubmed" id="18444971" target="_blank">18444971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9542675">
<a name="9542675"></a>Tausch I, Decroix J, Gwiedzdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. <i>Int J Dermatol.</i> 1998;37(2):140-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9542675/pubmed" id="9542675" target="_blank">9542675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Terbinafine.1">
<a name="Terbinafine.1"></a>Terbinafine [prescribing information]. Memphis, TN: Northstar Rx LLC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Terbinafine.2">
<a name="Terbinafine.2"></a>Terbinafine [prescribing information]. Princeton, NJ: OrchidPharma Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7671425">
<a name="7671425"></a>Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. <i>Clin Exp Dermatol</i>. 1995;20(3):247-248. doi:10.1111/j.1365-2230.1995.tb01314.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7671425/pubmed" id="7671425" target="_blank">7671425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Treat.2019">
<a name="Treat.2019"></a>Treat JR. Tinea capitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9496407">
<a name="9496407"></a>Trépanier EF, Amsden GW. Current issues in onychomycosis. <i>Ann Pharmacother</i>. 1998;32(2):204-214. doi:10.1345/aph.17006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9496407/pubmed" id="9496407" target="_blank">9496407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15115516">
<a name="15115516"></a>Ungpakorn R, Ayutyanont T, Reangchainam S, Supanya S. Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine. <i>Clin Exp Dermatol</i>. 2004;29(3):300-303. doi:10.1111/j.1365-2230.2004.01493.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/15115516/pubmed" id="15115516" target="_blank">15115516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10460803">
<a name="10460803"></a>Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.<i> Drug Metab Dispos</i>. 1999;27(9):1029-1038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10460803/pubmed" id="10460803" target="_blank">10460803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8089640">
<a name="8089640"></a>Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. <i>J Med Assoc Thai</i>. 1993;76(7):388-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/8089640/pubmed" id="8089640" target="_blank">8089640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29344845">
<a name="29344845"></a>Wang X, Yang Y, Li R, Yu J. Two cases of dermatophytic granuloma successfully treated with terbinafine. <i>Mycopathologia</i>. 2018;183(3):611-614. doi:10.1007/s11046-017-0237-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/29344845/pubmed" id="29344845" target="_blank">29344845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16198776">
<a name="16198776"></a>Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.<i> J Am Acad Dermatol</i>. 2005;53(4):578-584. doi:10.1016/j.jaad.2005.04.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/16198776/pubmed" id="16198776" target="_blank">16198776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1911319">
<a name="1911319"></a>White JE, Perkins PJ, Evans EG. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. <i>Br J Dermatol</i>. 1991;125(3):260-262. doi:10.1111/j.1365-2133.1991.tb14752.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/1911319/pubmed" id="1911319" target="_blank">1911319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8745918">
<a name="8745918"></a>White SI, Bowen-Jones D. Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics. <i>Br J Dermatol</i>. 1996;134(1):188-189. doi:10.1111/j.1365-2133.1996.tb07872.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/8745918/pubmed" id="8745918" target="_blank">8745918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26087080">
<a name="26087080"></a>Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: a randomized double-blind trial. <i>Indian J Dermatol Venereol Leprol</i>. 2015;81(4):363-9. doi:10.4103/0378-6323.158634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26087080/pubmed" id="26087080" target="_blank">26087080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30255495">
<a name="30255495"></a>Zaouak A, Ben Salem F, Charfi O, Hammami H, Fenniche S. Acute generalized exanthematous pustulosis induced by terbinafine in a child confirmed by patch testing. <i>Int J Dermatol</i>. 2019;58(2):e42-e43. doi:10.1111/ijd.14259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/30255495/pubmed" id="30255495" target="_blank">30255495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26938740">
<a name="26938740"></a>Zheng Y, Zhang J, Chen H, Lai W, Maibach HI. Terbinafine-induced lichenoid drug eruption. <i>Cutan Ocul Toxicol</i>. 2017;36(1):101-103. doi:10.3109/15569527.2016.1160101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/26938740/pubmed" id="26938740" target="_blank">26938740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28083794">
<a name="28083794"></a>Zhou S, Yang Y, Liu K, Huang S, Hu Y, Zhou X. A case report of widespread Majocchi's granuloma in a patient with systemic lupus erythematosus. <i>Mycopathologia</i>. 2017;182(5-6):577-581. doi:10.1007/s11046-017-0109-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/28083794/pubmed" id="28083794" target="_blank">28083794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33149920">
<a name="33149920"></a>Zhou S, Bagga A. Rhabdomyolysis and acute kidney injury associated with terbinafine use: a case report. <i>Can J Kidney Health Dis</i>. 2020;7:2054358120951371. doi:10.1177/2054358120951371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/33149920/pubmed" id="33149920" target="_blank">33149920</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15936 Version 364.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
